A Phase I Study of Lintuzumab Combined With Lenalidomide in Patients With Myelodysplastic Syndromes (MDS)
This study is a phase I, open-label, single-arm, dose escalation trial to determine the safety and activity of lenalidomide combined with lintuzumab in patients with MDS. Small groups of 3-6 patients will be treated with pre-specified doses of lenalidomide and lintuzumab and will receive 3-week cycles of combination therapy.
Myelodysplastic Syndrome (MDS)
DRUG: lintuzumab|DRUG: lenalidomide
The incidence of adverse events and lab abnormalities, 1 month after last dose
Antitumor activity, Every other 21-day cycle|Pharmacokinetic (PK) profile and immunogenicity (Human Anti-Human Antibody; HAHA), 1 month after last dose
This study is a phase I, open-label, single-arm, dose escalation trial to determine the safety and activity of lenalidomide combined with lintuzumab in patients with MDS. Small groups of 3-6 patients will be treated with pre-specified doses of lenalidomide and lintuzumab and will receive 3-week cycles of combination therapy.